Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections

Chemotherapy

Volumn 50, Issue 4, 2004, Pages 196-201

  Nenoff, P ^a,b   Haustein, U F ^b   Hittel, N ^c  

^a Lab F Medizinische Mikrobiologie   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Otsuka Pharmaceutical Co Ltd   (Germany)

Author keywords

Coagulase negative staphylococci; Fluoroquinolone; Minimum inhibitory concentration; Nadifloxacin; Propionibacteria; Staphylococcus aureus; Streptococci

Indexed keywords

ANTIINFECTIVE AGENT; CEFOTIAM; CLINDAMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; NADIFLOXACIN; OFLOXACIN; OXACILLIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DERMATITIS; DILUTION; FOLLICULITIS; IMPETIGO; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROPIONIBACTERIUM GRANULOSUM; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

ADMINISTRATION, TOPICAL; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; DNA DAMAGE; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLIZINES; SKIN DISEASES, BACTERIAL; STEREOISOMERISM;

EID: 8344236657     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081032     Document Type: Article

References (40)

1. Takahashi N, Shibahara T, Shiragiku T, Kanbe T, Kanbe K, Sugawara M, Yamashita S: Reduction of in vitro clastogenicity induced by the mixture of optical isomers of nadifloxacin during storage. Arzneimittelforschung 1995;45:195-197.
2. Kawabata S, Masada H, Wakebe H, Ohmori K, Tamaoka H: Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 2. Therapeutic effect of OPC-7251 cream on an experimental infection model in mice [in Japanese]. Jpn J Chemother 1989;37:1179-1183.
3. Kawabata S, Ohguro K, Mukai F, Ohmori K, Miyamoto H, Tamaoka H: Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1. In vitro antibacterial activity [in Japanese]. Jpn J Chemother 1989;37:1160-1178.
4. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S: Clinical and bacteriological evaluation of OPC-7251 in patients with acne: A double-blind group comparison study versus cream base. J Am Acad Dermatol 1991;25:674-681.
5. Nishijima S, Namura S, Akamatsu H, Kawai S, Asada Y, Kawabata S, Fujita M: In vitro activity of nadifloxacin against both methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus from patients with skin infections. Drugs 1995;49(suppl 2):230-232.
6. Nishijima S, Kurokawa I, Nakaya H: Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J Infect Chemother 2002;8:187-189.
7. Gollnick HPM, Vogt K, Herrmann J, Blume U, Hahn H, Haustein U-F, Orfanos CE: Topical quinolone OPC-7251: A clinical and microbiological study in acne. Eur J Dermatol 1994;4:210-215.
8. Haustein U-F, Nenoff P, Hittel N: Topical quinolone nadifloxacin (OPC-7251): A clinical and microbiological multicenter study in bacterial skin infection (abstract). Skin Pharmacol 1996;9:151.
9. Haustein U-F, Nenoff P, Hittel N: Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: Clinical evaluation in multicenter open trial and in vitro antimicrobiological susceptibility testing. J Dermatol Treat 1997;8:87-92.
10. Nenoff P, Haustein U-F, Hittel N: Nadifloxacin (OPC-7251) in acne vulgaris: Clinical evaluation and in vitro antibacterial activity (abstract). J Invest Dermatol 1997;108:392.
11. Nenoff P, Haustein U-F, Keller U: In vitro susceptibility of propionibacteria and staphylococci from acne patients to erythromycin. Eur J Acad Dermatol Venerol 1995;4:181-182.
12. Suh B, Lorber B: Quinolones. Med Clin North Am 1995;79:869-894.
13. Chu DT, Fernandes PB: Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother 1989;33:131-135.
14. Crumplin GC: Aspects of chemistry in the development of the 4-quinolone antibacterial agents. Rev Infect Dis 1988;10(suppl 1):S2-S9.
15. Domagala JM, Hanna LD, Heifetz CL, Hutt MP, Mich TF, Sanchez JP, Solomon M: New structure-activity relationships of the quinolone antibacterials using the target enzymes. The development and application of a DNA gyrase assay. J Med Chem 1986;29:394-404.
16. Oizumi N, Kawabata S, Hirao M, Watanabe K, Okuno S, Fujiwara T, Kikuchi M: Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother 2001;7:191-194.
17. Takei M, Fukuda H, Kishii R, Hosaka M: Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001;45:3544-3547.
18. Yamakawa T, Mitsuyama J, Hayashi K: In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002;49:455-465.
19. Bojar RA, Hittel N, Cunliffe WJ, Holland KT: Direct analysis of resistance in cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995;49(suppl 2):164-167.
20. Vogt K, Herrmann J, Blume U, Gollnick H, Hahn H, Haustein U-F, Orfanos CE: Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis 1992;11:943-945.
21. Vogt K, Hahn H, Herrmann J, Haustein UF, Blume U, Gollnick H, Orfanos CE: Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Drugs 1995;49(suppl 2):266-268.
22. Nishijima S, Kurokawa I, Kawabata S: Sensitivity of Propionibacterium acnes isolated from acne patients: Comparative study of antimicrobial agents. J Int Med Res 1996;24:473-477.
23. Nishijima S, Nakagawa M: Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients. J Int Med Res 1997;25:210-213.
24. Nishijima S, Kurokawa I, Katoh N, Watanabe K: The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000;27:318-323.
25. Kurokawa I, Nishijima S, Kawabata S: Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999;9:25-28.
26. Leyden JJ: Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001;15(suppl 3):51-55.
27. Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, Collignon P, Dreno B, Reynaud A, Fluhr J, Oshima S: Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001;144:339-346.
28. Nishijima S, Namura S, Akamatsu H, Kawai S, Asada Y, Kawabata S, Fujita M: Activity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections. J Dermatol 1995;22:153-155.
29. Nishijima S, Nakagawa M, Sugiyama T, Akamatsu H, Horio T, Kawabata S, Fujita M: Sensitivity of Staphylococcus aureus, isolated from skin infections in 1994, to 19 antimicrobial agents. J Int Med Res 1995;23:328-334.
30. Nishijima S, Nakagawa M, Tsuboi N, Akamatsu H, Horio T, Fujita M, Kawabata S: Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: Comparative study with seven other fluoroquinolones. J Int Med Res 1996;24:12-16.
31. Kimata H: Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur J Pediatr 1999;158:949.
32. Gollnick H, Schramm M: Topical drug treatment in acne. Dermatology 1998;196:119-125.
33. Komagata Y, Komiyama K, Nomura S: Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes. Jpn J Antibiot 1998;51:130-136.
34. Iwahara K, Ishii K, Chen Y, Miura Y: Tufted hair folliculitis: Response to topical therapy with nadifloxacin. Eur J Dermatol 1999;9:276-277.
35. Sreedharan S, Peterson LR, Fisher LM: Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: Role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1991;35:2151-2154.
36. Nishijima S, Kurokawa I, Nakaya H: Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J Infect Chemother 2002;8:187-189.
37. Jones RN: Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis 1991;15:177-179.
38. Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cotes H, Merlo A: Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother 1990;34:2050-2054.
39. Madhusudhan KT: Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test. Chemotherapy 2003;49:184-188.
40. Esposito S, Noviello S, Ianniello F: Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens. Chemotherapy 2000;46:309-314.